Clinical Trial Update: Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating antiproliferative effect of octreotide in patients with metastasized midgut neuroendocrine tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Carmen Schade-Brittinger | Conditions: Neuroendocrine Tumors | Phase 3 | Status: COMPLETED | Results posted: 2011-03-28